.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DC52_CefuroximeAndBetaLactama.CefuroximeAndBetaLactama .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DC52_CefuroximeAndBetaLactama.CefuroximeAndBetaLactama| name: | CefuroximeAndBetaLactamaseInhibitor | |
| ATC code: | J01DC52 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1500 | mg |
| volume of distribution: | 14 | L |
| clearance: | 100 | mL/min |
| other parameters in model implementation | ||
Cefuroxime is a second-generation cephalosporin antibiotic used to treat various bacterial infections. Beta-lactamase inhibitors are combined with beta-lactam antibiotics to overcome resistance caused by beta-lactamase producing bacteria. The combination is aimed at enhancing efficacy against beta-lactamase producing pathogens. There is no current approved combination of cefuroxime with a beta-lactamase inhibitor widely marketed under the ATC code J01DC52.
No published pharmacokinetic studies describing the parameters for the combination of cefuroxime and a beta-lactamase inhibitor were found. The following values are estimated based on known pharmacokinetic properties of intravenous cefuroxime in healthy adult subjects.